The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
Sodium-glucose cotransporter-2 (SGLT-2) is a high-capacity, low-affinity transporter expressed almost exclusively in the S1 segment of the proximal renal tubule, responsible for reabsorbing approximately 90% of the 180g of glucose filtered daily by the glomerulus. In type 2 diabetes, upregulated SGLT-2 expression contributes to sustained hyperglycaemia by increasing the renal glucose threshold. SGLT-2 inhibitors competitively block this transporter, inducing glucosuria of 60–90g per day, which reduces plasma glucose independently of insulin secretion or action — a mechanism that is effective even in insulin-deficient states.
Beyond glycaemic control, SGLT-2 inhibition produces osmotic diuresis and natriuresis, reducing plasma volume and consequently cardiac preload and afterload. Tubuloglomerular feedback activation — via increased sodium delivery to the macula densa — causes afferent arteriole vasoconstriction, reducing intraglomerular pressure and providing nephroprotection independent of blood glucose lowering. Large cardiovascular and renal outcome trials (EMPA-REG OUTCOME, DAPA-HF, EMPEROR-Reduced, DAPA-CKD, CREDENCE) have demonstrated significant reductions in heart failure hospitalisation, cardiovascular death, and CKD progression across patients with and without diabetes.
The haemodynamic and metabolic effects of SGLT-2 inhibition are now understood to extend well beyond glucose lowering. Increased ketone body production (beta-hydroxybutyrate) provides an alternative myocardial energy substrate — the thrifty substrate hypothesis — potentially improving cardiac energetics in the failing heart. SGLT-2 inhibitors are now guideline-recommended in heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and CKD with albuminuria, regardless of diabetes status, reflecting a fundamental repositioning from antidiabetic to cardiorenal protective agents.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
Clinically actionable insights for treatment selection and sequencing
Sodium-glucose cotransporter-2 (SGLT-2) is a high-capacity, low-affinity transporter expressed almost exclusively in the S1 segment of the proximal renal tubule, responsible for reabsorbing approximately 90% of the 180g of glucose filtered daily by the glomerulus.
In type 2 diabetes, upregulated SGLT-2 expression contributes to sustained hyperglycaemia by increasing the renal glucose threshold.
SGLT-2 inhibitors competitively block this transporter, inducing glucosuria of 60–90g per day, which reduces plasma glucose independently of insulin secretion or action — a mechanism that is effective even in insulin-deficient states.
Beyond glycaemic control, SGLT-2 inhibition produces osmotic diuresis and natriuresis, reducing plasma volume and consequently cardiac preload and afterload.
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Cardiology / Cardiovascular Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →